UV1 Peptide Vaccine With Olaparib and Durvalumab Missed Its Main Goal in Recurrent Ovarian Cancer in the DOVACC Trial
In the randomized Phase 2 DOVACC trial (NCT04742075) of 188 patients with BRCA wild-type recurrent ovarian cancer, adding UV1, a vaccine of three synthetic long peptides from the telomerase protein hTERT, to olaparib and durvalumab gave a median progression-free survival of 8.7 months vs. 5.9 months on olaparib alone (hazard ratio 0.83, 95% CI 0.68 to 1.01, P = .066), short of statistical significance. OncLive reported on November 9 on the results, presented at the ESMO Congress in October, including exploratory subgroups such as HRD-negative patients (HR 0.73) that would need confirmation.